GlassScriptPhysician profile
Thomas S Glasgow
NPI 1316913783
$2,531.89
in general payments reported to CMS, 2019-2025
28 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $242 · 2021: $524 · 2022: $509 · 2023: $364 · 2024: $290 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $983.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $559.94 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $224.52 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $218.28 | 2021-2025 | |
| Novo Nordisk INC | $155.34 | 2020-2025 | Wegovy, Ozempic, Saxenda |
| Janssen Pharmaceuticals, INC | $153.03 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.40 | 2019-2020 | |
| Amgen INC. | $132.48 | 2022-2025 | Evenity |
| Corcept Therapeutics | $128.13 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2021 | |
| Pfizer INC. | $86.28 | 2020-2025 | |
| Lilly USA, LLC | $73.28 | 2022-2025 | Zepbound, Jardiance |
| Daiichi Sankyo INC. | $70.04 | 2022 | |
| Nestle Healthcare Nutrition INC. | $61.99 | 2021-2022 | |
| Mylan Specialty L.P. | $58.56 | 2019-2024 | Yupelri |
| Amarin Pharma, INC. | $46.87 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.17 | 2022-2023 | |
| Astellas Pharma US INC | $34.39 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $33.25 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $33.03 | 2019-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $26.89 | 2022 | |
| Dexcom, INC. | $25.93 | 2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $21.05 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.22 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.20 | 2023 | Quviviq |
| Ironwood Pharmaceuticals, INC | $13.92 | 2024 | |
| Sunovion Pharmaceuticals INC. | $12.83 | 2019 | |
| Boston Scientific Corporation | $11.83 | 2019 | |
| Merck Sharp & Dohme LLC | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Glasgow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.